AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight

RecruitingPhase 3Ages 18 Years - anyAllNovo Nordisk A/S
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

The purpose of this study is to see how oral semaglutide, when taken in lower doses help lowering of body weight in participants with excess body weight when compared to 'dummy' tablets (placebo). Results from this study will help select the most optimal lower dose of oral semaglutide that can be used for treating participants living with overweight or obesity.

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study. * Female or male (sex at birth). * Age 18 years or above at the time of signing the informed consent. * Body mass index (BMI) of 1. โ‰ฅ 27.0 kilogram per square meter (kg/m\^2) with the presence of at least one weight-related comorbidity including, but not limited to, hypertension, dyslipidaemia, obstructive sleep apnoea or CV disease. OR 2. โ‰ฅ 30.0 kg/m\^2. * History of at least one self-reported unsuccessful dietary effort to lose body weight. Exclusion Criteria: * A self-reported change in body weight greater than (\>) 5% within 90 days before screening irrespective of medical records. * HbA1c โ‰ฅ 6.5% (48 millimoles per mole \[mmol/mol\]) as measured by the central laboratory at screening. * Consistent use of glucagon like peptide-1 (GLP-1) receptor agonists, including medication with glucagon like peptide-1 receptor agonist (GLP-1 RA) activity like dual GLP-1/gastric inhibitory peptide RAs, or amylin analogues before screening. Consistent use is defined as treatment.
๐Ÿ’Š

What it tests

  • Semaglutide
  • Placebo
๐Ÿ“

Where

62 sites
Uni of Alabama at Birmingham
Birmingham, United States
Headlands Research California, LLC
Escondido, United States
National Research Institute - Huntington Park
Huntington Park, United States
Los Angeles Institute for Metabolic Research
Los Angeles, United States
ERG Holding Company, LLC / Evolution Research Group, LLC
Delray Beach, United States
ERG Holding Company, LLC / Evolution Research Group, LLC
Fort Myers, United States
Jedidiah Clinical Research
Tampa, United States
East West Med Res Inst
Honolulu, United States

โ€ฆand 54 more on ClinicalTrials.gov.

๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy